Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Oct 15, 2026; 18(10): 121745
Published online Oct 15, 2026. doi: 10.4251/wjgo.121745
Published online Oct 15, 2026. doi: 10.4251/wjgo.121745
Table 2 Participant characteristics (n = 70), n (%)
| Overall | Korea | Malaysia | Philippines | Singapore | Taiwan | Thailand | Vietnam | |
| Specialty | ||||||||
| Medical oncologist | 31 (44.3) | 3 (30.0) | 6 (60.0) | 5 (50.0) | 4 (40.0) | 2 (20.0) | 6 (60.0) | 5 (50.0) |
| Gastroenterologist/hepatologist | 24 (34.3) | 6 (60.0) | - | 3 (30.0) | 4 (40.0) | 7 (70.0) | 2 (20.0) | 2 (20.0) |
| Surgeon | 7 (10.0) | - | 2 (20.0) | 1 (10.0) | 2 (20.0) | 1 (10.0) | - | 1 (10.0) |
| Interventional radiologist | 8 (11.4) | 1 (10.0) | 2 (20.0) | 1 (10.0) | - | - | 2 (20.0) | 2 (20.0) |
| Healthcare setting | ||||||||
| Public only | 21 (30.0) | 5 (50.0) | 4 (40.0) | - | 3 (30.0) | 4 (40.0) | 1 (10.0) | 4 (40.0) |
| Private only | 18 (25.7) | 3 (30.0) | 3 (30.0) | 4 (40.0) | 7 (70.0) | 1 (10.0) | - | - |
| Both public and private | 31 (44.3) | 2 (20.0) | 3 (30.0) | 6 (60.0) | - | 5 (50.0) | 9 (90.0) | 6 (60.0) |
| Primary institution | ||||||||
| National or regional cancer centre | 34 (48.6) | 7 (70.0) | 3 (30.0) | 1 (10.0) | 2 (20.0) | 8 (80.0) | 8 (80.0) | 5 (50.0) |
| Large or mid-sized regional hospital | 20 (28.6) | 3 (30.0) | 4 (40.0) | 3 (30.0) | 3 (30.0) | 1 (10.0) | 1 (10.0) | 5 (50.0) |
| Private clinic/practice | 12 (17.1) | - | 2 (20.0) | 4 (40.0) | 5 (50.0) | 1 (10.0) | - | - |
| Other | 4 (5.7) | - | 1 (10.0) | 2 (20.0) | - | - | 1 (10.0) | - |
| Role at primary institution | ||||||||
| Junior doctor/resident | 1 (1.4) | - | - | - | - | - | - | 1 (10.0) |
| Consultant | 34 (48.6) | - | 9 (90.0) | 9 (90.0) | 6 (60.0) | - | 2 (20.0) | 8 (80.0) |
| Assistant/associate professor | 22 (31.4) | 4 (40.0) | 2 (20.0) | 2 (20.0) | 1 (10.0) | 3 (30.0) | 8 (80.0) | 2 (20.0) |
| Professor | 16 (22.9) | 5 (50.0) | 1 (10.0) | 1 (10.0) | 2 (20.0) | 6 (60.0) | 1 (10.0) | - |
| Leadership position | 29 (41.4) | 4 (40.0) | 3 (30.0) | 5 (50.0) | 2 (20.0) | 5 (50.0) | 3 (30.0) | 7 (70.0) |
| Other | 3 (4.3) | - | - | - | 1 (10.0) | 2 (20.0) | - | - |
| Licensed to prescribe systemic therapies for HCC | 54 (77.1) | 9 (90.0) | 7 (70.0) | 9 (90.0) | 5 (50.0) | 10 (100.0) | 8 (80.0) | 6 (60.0) |
| Leadership position in a medical society | 17 (24.3) | 3 (30.0) | 2 (20.0) | 3 (30.0) | 2 (20.0) | 2 (20.0) | 2 (20.0) | 3 (30.0) |
| Mean length of experience, years (SD) | 18.0 (10.1) | 16.3 (7.1) | 12.9 (4.1) | 15.5 (3.9) | 21.4 (8.7) | 24.7 (19.7) | 17.8 (5.3) | 17.3 (6.5) |
| Mean patients with HCC assessed annually, n (SD) | 294.5 (604.9) | 769.0 (971.0) | 69.2 (80.9) | 63.2 (54.2) | 39.8 (39.3) | 223.7 (264.7) | 152.5 (164.5) | 744.0 (942.6) |
| Mean total patients managed who have HCC, % (SD) | 27.6 (26.2) | 46.5 (28.1) | 20.5 (23.1) | 19.0 (19.2) | 19.4 (22.3) | 23.5 (20.0) | 23.0 (24.3) | 42.0 (29.3) |
- Citation: Tanasanvimon S, Cheng PN, Kang W, Ho GF, Pham TA, Cabato M, Husni RE, Kim BY, Chow P. Evolving practices, treatment decisions, and unmet needs in intermediate-stage hepatocellular carcinoma: An Asia Pacific perspective. World J Gastrointest Oncol 2026; 18(10): 121745
- URL: https://www.wjgnet.com/1948-5204/full/v18/i10/121745.htm
- DOI: https://dx.doi.org/10.4251/wjgo.121745